Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM) Meeting Abstract
| Authors: | Kubicki, T.; Dytfeld, D.; Wrobel, T.; Jamroziak, K.; Robak, P.; Czyz, J.; Tyczynska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Nowicki, A.; Szczepaniak, T.; Lojko-Dankowska, A.; Matuszak, M.; Gil, L.; Pula, B. M.; Rybka, J.; Majcherek, M.; Usnarska-Zubkiewicz, L.; Szukalski, L.; Konska, A.; Zaucha, J. M.; Walewski, J.; Mikulski, D.; Czabak, O.; Robak, T.; Kruk-Kwapisz, D.; Lahoud, O. B.; Zonder, J. A.; Griffith, K.; Stefka, A. T.; Jiang, K.; Cooperrider, J. H.; Derman, B. A.; Jakubowiak, A. J. |
| Abstract Title: | Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4715 |
| Language: | English |
| ACCESSION: | WOS:001159740308204 |
| DOI: | 10.1182/blood-2023-189850 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
